Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Mounjaro is not designed to be taken twice a week, and taking tirzepatide twice a week would not follow the licensed dosing schedule. Each pre-filled KwikPen contains four weekly doses, and the whole point of the once-weekly design is to keep the medicine at a steady level in your body. Splitting or doubling doses changes that profile in ways your prescriber hasn't accounted for. As a prescription-only medicine, the schedule is set by a GPhC-registered prescriber after clinical assessment — not something to adjust independently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a reasonable thought. The logic goes: if one injection a week works, would two work faster? The answer is no, and the reason sits in how tirzepatide behaves in the body. Once injected under the skin, the medicine is absorbed slowly and then cleared slowly. Its half-life is roughly five days, which is exactly why a once-weekly schedule produces a stable, predictable blood concentration. Inject it again mid-week and you don't double the effect, you stack doses on top of a level that hasn't cleared, pushing concentrations well above the range your prescriber calibrated for. The NHS patient information for tirzepatide is clear that Mounjaro is a once-weekly injection, full stop.
The four-dose KwikPen format reinforces this. Each pen is designed to deliver one injection per week across a four-week supply. There's no clinical or practical basis in the UK licensed schedule for taking Mounjaro twice a week, something our clinical team is asked about often enough that we've put together a dedicated explanation of why the licensed schedule is structured the way it is. If you've seen discussion of twice-weekly tirzepatide dosing online, it's likely referring to research protocols or off-label practices outside the UK, not something a UK prescriber would recommend under the current licensed indication.
Side effects from Mounjaro are heavily GI-led: nausea, vomiting, diarrhoea, constipation, reflux. The once-weekly titration schedule (starting at 2.5 mg and moving up in roughly four-week steps) exists specifically to minimise these. The first pen's job is settling your system rather than producing weight loss; the therapeutic work comes at higher doses once tolerance is established. Doubling the frequency of injections bypasses that tolerance-building entirely. The result would likely be a sharp spike in side effects, not an acceleration of results.
There are also safety considerations beyond nausea. The prescriber who sets your schedule has assessed your full clinical picture, other medicines, medical history, current weight. Changing the frequency independently removes you from the clinical framework that makes treatment safe. This is one reason why Mounjaro is a prescription-only medicine: the dosing decisions stay with the prescriber, not with the patient acting on intuition. If the current schedule feels slow or ineffective, that conversation belongs in a clinical review, not a DIY adjustment on a Tuesday afternoon.
For those curious about what a flexible schedule might look like, the more nuanced question isn't about frequency but about what happens if you miss a week, which is an entirely separate clinical question with its own guidance.
The UK licensed schedule for tirzepatide runs through six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Titration is typically in four-week steps, though the pace is set by the prescriber based on how well the treatment is tolerated. The NICE appraisal of tirzepatide (TA1026) reviewed the clinical evidence for this schedule extensively before recommending it for adults with a BMI of 35 or above alongside at least one weight-related comorbidity, within the NHS framework.
On a private basis (which is how nume prescribes for patients who don't meet NHS criteria or prefer not to wait) the same licensed schedule applies. The prescriber reviews the patient's response at each stage before any dose change proceeds. The idea that taking Mounjaro twice a week could accelerate progress assumes the problem is frequency, when in practice most patients find the bottleneck is simply time at each dose level while the body adapts. Patience with the schedule, not departure from it, is what the clinical evidence actually supports.
If you want to understand how the schedule works in practice before starting, our guide to Mounjaro's once-weekly dosing covers the full picture. There's also useful background on microdosing practices that some patients ask about, though these fall firmly outside the licensed schedule too. The treatment overview at our weight-loss treatments page is the right starting point if you're ready to speak to a prescriber about what's appropriate for your situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.